PMC:7499584 / 13623-14328 JSONTXT

Annnotations TAB JSON ListView MergeView

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7499584","sourcedb":"PMC","sourceid":"7499584","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7499584","text":"Coagulopathies and heparin treatment are the subject of several articles regarding the pathology of COVID19 (Becker 2020; Porfidia and Pola 2020), and heparan sulfate derivatives and sulfated oligosaccharides appear from several laboratories to play a role in the binding of spike protein to the ACE2 receptor (Clausen et al. 2020; Kim et al. 2020; Kwon et al. 2020; Mycroft-West et al. 2020; Tandon et al. 2020; Zhang et al. 2020). Thus, heparan sulfate derived or sulfated nonanticoagulant and anticoagulant oligosaccharides and derivatives may be effective interdictors of both viral infectivity and coagulopathies, and FDA-approved heparinoid products should be considered for repurposing for COVID19.","tracks":[{"project":"2_test","denotations":[{"id":"32829416-32415579-45163186","span":{"begin":116,"end":120},"obj":"32415579"},{"id":"32829416-32367471-45163187","span":{"begin":140,"end":144},"obj":"32367471"},{"id":"32829416-32714563-45163188","span":{"begin":361,"end":365},"obj":"32714563"},{"id":"T46096","span":{"begin":116,"end":120},"obj":"32415579"},{"id":"T36381","span":{"begin":140,"end":144},"obj":"32367471"},{"id":"T29758","span":{"begin":361,"end":365},"obj":"32714563"}],"attributes":[{"subj":"32829416-32415579-45163186","pred":"source","obj":"2_test"},{"subj":"32829416-32367471-45163187","pred":"source","obj":"2_test"},{"subj":"32829416-32714563-45163188","pred":"source","obj":"2_test"},{"subj":"T46096","pred":"source","obj":"2_test"},{"subj":"T36381","pred":"source","obj":"2_test"},{"subj":"T29758","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#e993ec","default":true}]}]}}